Spectral AI

Dallas’ Spectral AI Appoints Chief Commercialization Officer

by | May 31, 2024

Dallas-based artificial intelligence company Spectral AI Inc. has appointed Jeremiah A. Sparks as chief commercialization officer. Spectral AI focuses on medical diagnostics for faster and more accurate treatment decisions in wound care.

Sparks brings over 20 years of medical device marketing experience, including global marketing and business strategy. He will be responsible for both domestic and international product commercialization, the company said....

MORE
Spectral AI Names CEO of Its IP-Focused Subsidiary, Explores Spin Off
by | Apr 26, 2024
The largest investor in Spectral AI, Erich Spangenberg, has extensive expertise in intellectual property investment management.
MORE
D CEO and Dallas Innovates revealed the winners of the 2024 Innovation Awards at an event on January 24, 2023 held at On the Levee in the Design District.
Meet the Winners:
D CEO, Dallas Innovates Honor Top Innovators at 2024 Awards
At the annual Innovation Awards event, Dallas Innovates and D CEO revealed the winners in 17 categories and recognized all 74 North Texas finalists.
MORE
Spectral AI Names Former Top MiMedx Financial Exec as CFO
by | Dec 27, 2023

Seasoned financial executive Peter M. Carlson has been hired as chief financial officer of Dallas-based Spectral AI Inc., an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care....

MORE

Spectral AI Names EVP to Spearhead UK Subsidiary, Global Expansion of Imaging Tech

by | Oct 27, 2023
Spectral AI has recently secured its largest contract to date from the U.S. government, an award exceeding $149 million, boosting its total U.S. government awards accrued since 2019 to more than $246 million, as it aims to revolutionize wound care. The company's DeepView SnapShot Wound Imaging System, has received UK Conformity Assessed (UKCA) marking for use in the United Kingdom and has been classified as a Class 1 medical device by U.S. FDA.
MORE
Spectral AI Appoints ‘High-Impact’ Healthcare Exec to its Board of Directors
by | Oct 6, 2023
In September, the firm began trading on Nasdaq and secured a BARDA Project BioShield contract worth up to $149 million.
MORE
Spectral MD Awarded BARDA Project BioShield Contract Worth Up to $149M
by | Sep 28, 2023
The contract is for the advanced development of Spectral MD's DeepView System, an AI-driven burn wound imaging device designed to be used at emergency departments, trauma centers, and burn centers.
MORE
Dallas’ Spectral MD Offers Updates in Run-Up to Its Nasdaq Listing as Spectral AI
by | Aug 29, 2023
With $130 million in government funding supporting its AI-powered wound-prediction tech as a triage tool for burn victims in a mass casualty event, Dallas-based Spectral MD is nearing its listing on Nasdaq via a SPAC merger. Its listing as "Spectral AI" is slated for September 8 or 11, and the company offered updates on how it's going—revealing the nuts & bolts of how such transactions work.
MORE